Autolus Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional ADSs
February 12 2021 - 4:01PM
Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage
biopharmaceutical company developing next-generation programmed T
cell therapies, today announced the closing of its previously
announced underwritten public offering in the United States of
16,428,572 American Depositary Shares (“ADSs”) representing
16,428,572 ordinary shares, including the exercise in full by the
underwriters of their option to purchase an additional 2,142,857
ADSs, at a public offering price of $7.00 per ADS. The gross
proceeds to Autolus from the offering, before underwriting
discounts and commissions and other offering expenses payable by
Autolus, were approximately $115.0 million.
J.P. Morgan and Wells Fargo Securities acted as
joint bookrunners for the offering. Kempen & Co, Mizuho
Securities and Needham & Company acted as co-managers.
The securities described above were offered by
Autolus pursuant to an effective shelf registration statement that
was previously filed with the Securities and Exchange Commission
(“SEC”). A final prospectus supplement to the accompanying
prospectus describing the terms of the offering was filed with the
SEC. Copies of the final prospectus supplement and the accompanying
prospectus relating to the offering may be obtained for free from
either of the joint book-running managers for the offering, J.P.
Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155
Long Island Avenue, Edgewood, NY 11717, or by telephone at +1 866
803 9204 or by email at prospectus-eq_fi@jpmchase.com; or Wells
Fargo Securities, LLC, Attention: Equity Syndicate Department, 500
West 33rd Street, New York, New York, 10001, at (800) 326-5897 or
email a request to cmclientsupport@wellsfargo.com. For the
avoidance of doubt, such prospectus will not constitute a
"prospectus" for the purposes of the Regulation (EU) 2017/1129 and
has not been reviewed by any competent authority in any member
state in the European Economic Area or the United Kingdom.
This press release does not constitute an offer
to sell or the solicitation of an offer to buy securities, and
shall not constitute an offer, solicitation or sale in any
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of that jurisdiction.
About Autolus
Autolus is a clinical-stage biopharmaceutical
company developing next-generation, programmed T cell therapies for
the treatment of cancer. Using a broad suite of proprietary and
modular T cell programming technologies, the company is engineering
precisely targeted, controlled and highly active T cell therapies
that are designed to better recognize cancer cells, break down
their defense mechanisms and eliminate these cells. Autolus has a
pipeline of product candidates in development for the treatment of
hematological malignancies and solid tumors.
Contacts:
Lucinda Crabtree, Ph.D.Vice President, Investor Relations and
Corporate Communications+44 (0)7587 372
619l.crabtree@autolus.com
Julia Wilson+44 (0)7818 430877j.wilson@autolus.com
Susan A NoonanS.A. Noonan Communications, LLC+1 212 966
3650susan@sanoonan.com
Autolus Therapeutics (NASDAQ:AUTL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Autolus Therapeutics (NASDAQ:AUTL)
Historical Stock Chart
From Apr 2023 to Apr 2024